Brokerages Set GRAIL, Inc. (NASDAQ:GRAL) Price Target at $67.00

GRAIL, Inc. (NASDAQ:GRAL) has been given a consensus recommendation of “Hold” by the ten ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $67.00.

A number of brokerages recently weighed in on GRAL. Wolfe Research began coverage on shares of GRAIL in a report on Tuesday, June 2nd. They set a “peer perform” rating for the company. TD Cowen lifted their price objective on shares of GRAIL from $65.00 to $69.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Wall Street Zen upgraded shares of GRAIL from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Mizuho began coverage on shares of GRAIL in a report on Friday, April 10th. They set a “neutral” rating and a $58.00 price objective for the company. Finally, The Goldman Sachs Group assumed coverage on shares of GRAIL in a report on Friday, June 5th. They set a “neutral” rating and a $60.00 price objective for the company.

GRAIL Price Performance

Shares of GRAL opened at $68.27 on Wednesday. GRAIL has a 1-year low of $29.95 and a 1-year high of $118.84. The company has a 50-day moving average of $61.38 and a 200 day moving average of $70.98. The firm has a market capitalization of $2.93 billion, a price-to-earnings ratio of -6.58 and a beta of 3.15.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($2.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.76) by $0.47. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. The company had revenue of $40.79 million during the quarter, compared to analyst estimates of $39.16 million. On average, equities analysts anticipate that GRAIL will post -10.91 earnings per share for the current fiscal year.

Insider Buying and Selling at GRAIL

In other news, insider Andrew John Partridge sold 1,491 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $61.08, for a total value of $91,070.28. Following the completion of the sale, the insider owned 163,738 shares in the company, valued at approximately $10,001,117.04. The trade was a 0.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Robert P. Ragusa sold 123,502 shares of the business’s stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $6,165,219.84. Following the completion of the sale, the chief executive officer owned 518,582 shares of the company’s stock, valued at approximately $25,887,613.44. This represents a 19.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 232,464 shares of company stock worth $11,621,242. 1.83% of the stock is owned by company insiders.

Institutional Investors Weigh In On GRAIL

Several large investors have recently modified their holdings of GRAL. WIM INVESTMENT MANAGEMENT Ltd grew its position in GRAIL by 200.0% during the 3rd quarter. WIM INVESTMENT MANAGEMENT Ltd now owns 63,000 shares of the company’s stock worth $3,725,000 after purchasing an additional 42,000 shares during the last quarter. JPMorgan Chase & Co. grew its position in GRAIL by 159.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 206,120 shares of the company’s stock worth $12,188,000 after purchasing an additional 126,576 shares during the last quarter. Farallon Capital Management LLC grew its position in GRAIL by 168.7% during the 3rd quarter. Farallon Capital Management LLC now owns 1,349,000 shares of the company’s stock worth $79,766,000 after purchasing an additional 847,000 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in GRAIL by 154,361.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 91,132 shares of the company’s stock worth $7,531,000 after purchasing an additional 91,073 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in GRAIL by 9.0% during the 4th quarter. Vanguard Group Inc. now owns 1,980,783 shares of the company’s stock worth $169,535,000 after purchasing an additional 163,790 shares during the last quarter.

Key GRAIL News

Here are the key news stories impacting GRAIL this week:

• Neutral Sentiment: Several law firms, including Faruqi & Faruqi, Rosen, Pomerantz, Schall, Glancy Prongay Wolke & Rotter, Levi & Korsinsky, Bronstein Gewirtz & Grossman, and Robbins Geller, issued investor alerts about the ongoing securities class action and the approaching August 4 lead-plaintiff deadline. Article: GRAL INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026
• Neutral Sentiment: The lawsuits stem from allegations that GRAIL misrepresented or overstated its NHS-Galleri trial results, and multiple reports say the company lost more than $2.2 billion in market value after the February 20 trial readout disappointed investors. Article: GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout — HBSS
• Negative Sentiment: The repeated legal headlines reinforce investor concerns about possible fraud claims, potential liability, and reputational damage, which can weigh on sentiment toward GRAIL shares. Article: $GRAL Notification: GRAIL, Inc. Accused of Misrepresentations about its Trial Results in Securities Fraud Class Action

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.